The Experts below are selected from a list of 483 Experts worldwide ranked by ideXlab platform
Suzanne K Vosburg - One of the best experts on this subject based on the ideXlab platform.
-
CLINICAL SCIENCE Dronabinol and Marijuana in HIV-Positive Marijuana Smokers Caloric Intake, Mood, and Sleep
2015Co-Authors: Margaret Haney, Carl L Hart, Suzanne K Vosburg, Erik W Gunderson, Judith Rabkin, Ra D. Comer, Richard W FoltinAbstract:Objectives: Individuals with HIV constitute the largest group using cannabinoids for medicinal reasons; yet, no studies have directly compared the tolerability and efficacy of smoked marijuana and oral Dronabinol maintenance in HIV-positive marijuana smokers. This placebo-controlled within-subjects study evaluated marijuana and Dronabinol across a range of behaviors: eating topography, mood, cognitive performance, physiologic measures, and sleep. Methods: HIV-positive marijuana smokers (n = 10) completed 2 16-day inpatient phases. Each Dronabinol (5 and 10 mg) and marijuana (2.0 % and 3.9 % D9-tetrahydrocannabinol [THC]) dose was administered 4 times daily for 4 days, but only 1 drug was active per day, thereby maintaining double-blind dosing. Four days of placebo washout separated each active cannabinoid condition. Results: As compared with placebo, marijuana and Dronabinol dose dependently increased daily caloric intake and body weight in HIV-positive marijuana smokers. All cannabinoid conditions produced significant intoxication, except for low-dose Dronabinol (5 mg); the intoxication was rated positively (eg, ‘‘good drug effect’’) with little evidence of discomfort and no impairment of cognitive performance. Effects of marijuana and Dronabinol were comparable, except that only marijuana (3.9 % THC) improved ratings of sleep. Conclusions: These data suggest that for HIV-positive marijuana smokers, both Dronabinol (at doses 8 times current recommendations) and marijuana were well tolerated and produced substantial and comparable increases in food intake
-
nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse
Neuropsychopharmacology, 2013Co-Authors: Margaret Haney, Suzanne K Vosburg, Gillinder Bedi, Ziva D Cooper, Sandra D Comer, Richard W FoltinAbstract:Few individuals seeking treatment for marijuana use achieve sustained abstinence. The cannabinoid receptor agonist, Δ(9)-tetrahydrocannabinol (THC; Dronabinol), decreases marijuana withdrawal symptoms, yet does not decrease marijuana use in the laboratory or clinic. Dronabinol has poor bioavailability, which may contribute to its poor efficacy. The FDA-approved synthetic analog of THC, nabilone, has higher bioavailability and clearer dose-linearity than Dronabinol. This study tested whether nabilone administration would decrease marijuana withdrawal symptoms and a laboratory measure of marijuana relapse relative to placebo. Daily, nontreatment-seeking marijuana smokers (8 men and 3 women), who reported smoking 8.3±3.1 marijuana cigarettes/day completed this within-subject study comprising three, 8-day inpatient phases; each phase tested a different nabilone dose (0, 6, 8 mg/day, administered in counter-balanced order on days 2-8). On the first inpatient day, participants took placebo capsules and smoked active marijuana (5.6% THC) at six timepoints. For the next 3 days, they had the opportunity to self-administer placebo marijuana (0.0% THC; withdrawal), followed by 4 days in which active marijuana was available for self-administration (5.6% THC; relapse). Both nabilone dose conditions decreased marijuana relapse and reversed withdrawal-related irritability and disruptions in sleep and food intake (p<0.05). Nabilone (8 mg/day) modestly worsened psychomotor task performance. Neither dose condition increased ratings of capsule 'liking' or desire to take the capsules relative to placebo. Thus, nabilone maintenance produced a robust attenuation of marijuana withdrawal symptoms and a laboratory measure of relapse even with once per day dosing. These data support testing of nabilone for patients seeking marijuana treatment.
-
Dronabinol and marijuana in hiv positive marijuana smokers caloric intake mood and sleep
Journal of Acquired Immune Deficiency Syndromes, 2007Co-Authors: Erik W Gunderson, Carl L Hart, Judith G Rabkin, Suzanne K VosburgAbstract:Objectives: Individuals with HIV constitute the largest group using cannabinoids for medicinal reasons; yet, no studies have directly compared the tolerability and efficacy of smoked marijuana and oral Dronabinol maintenance in HIV-positive marijuana smokers. This placebo-controlled within-subjects study evaluated marijuana and Dronabinol across a range of behaviors: eating topography, mood, cognitive performance, physiologic measures, and sleep. Methods: HIV-positive marijuana smokers (n = 10) completed 2 16-day inpatient phases. Each Dronabinol (5 and 10 mg) and marijuana (2.0% and 3.9% D 9 -tetrahydrocannabinol [THC]) dosewas administered 4 times daily for 4 days, but only 1 drug was active per day, thereby maintaining double-blind dosing. Four days of placebo washout separated each active cannabinoid condition. Results: As compared with placebo, marijuana and Dronabinol dose dependently increased daily caloric intake and body weight in HIVpositive marijuana smokers. All cannabinoid conditions produced significant intoxication, except for low-dose Dronabinol (5 mg); the intoxication was rated positively (eg, ‘‘good drug effect’’) with little evidence of discomfort and no impairment of cognitive performance. Effects of marijuana and Dronabinol were comparable, except that only marijuana (3.9% THC) improved ratings of sleep. Conclusions: These data suggest that for HIV-positive marijuana smokers, both Dronabinol (at doses 8 times current recommendations) and marijuana were well tolerated and produced substantial and comparable increases in food intake.
-
Dronabinol and marijuana in hiv positive marijuana smokers caloric intake mood and sleep
Journal of Acquired Immune Deficiency Syndromes, 2007Co-Authors: Erik W Gunderson, Carl L Hart, Judith G Rabkin, Suzanne K VosburgAbstract:OBJECTIVES: Individuals with HIV constitute the largest group using cannabinoids for medicinal reasons; yet, no studies have directly compared the tolerability and efficacy of smoked marijuana and oral Dronabinol maintenance in HIV-positive marijuana smokers. This placebo-controlled within-subjects study evaluated marijuana and Dronabinol across a range of behaviors: eating topography, mood, cognitive performance, physiologic measures, and sleep. METHODS: HIV-positive marijuana smokers (n = 10) completed 2 16-day inpatient phases. Each Dronabinol (5 and 10 mg) and marijuana (2.0% and 3.9% Delta9-tetrahydrocannabinol [THC]) dose was administered 4 times daily for 4 days, but only 1 drug was active per day, thereby maintaining double-blind dosing. Four days of placebo washout separated each active cannabinoid condition. RESULTS: As compared with placebo, marijuana and Dronabinol dose dependently increased daily caloric intake and body weight in HIV-positive marijuana smokers. All cannabinoid conditions produced significant intoxication, except for low-dose Dronabinol (5 mg); the intoxication was rated positively (eg, "good drug effect") with little evidence of discomfort and no impairment of cognitive performance. Effects of marijuana and Dronabinol were comparable, except that only marijuana (3.9% THC) improved ratings of sleep. CONCLUSIONS: These data suggest that for HIV-positive marijuana smokers, both Dronabinol (at doses 8 times current recommendations) and marijuana were well tolerated and produced substantial and comparable increases in food intake.
Johannes G. Ramaekers - One of the best experts on this subject based on the ideXlab platform.
-
Comparing treatment effects of oral THC on simulated and on-the-road driving performance: Testing the validity of driving simulator drug research
Psychopharmacology, 2015Co-Authors: J. L. Veldstra, W. M. Bosker, Johannes G. Ramaekers, Dick De Waard, Karel A. BrookhuisAbstract:RATIONALE: The driving simulator provides a safe and controlled environment for testing driving behaviour efficiently. The question is whether it is sensitive to detect drug-induced effects.\n\nOBJECTIVE: The primary aim of the current study was to investigate the sensitivity of the driving simulator for detecting drug effects. As a case in point, we investigated the dose-related effects of oral ∆(9)-tetrahydrocannabinol (THC), i.e. Dronabinol, on simulator and on-the-road driving performance in equally demanding driving tasks.\n\nMETHOD: Twenty-four experienced driver participants were treated with Dronabinol (Marinol®; 10 and 20 mg) and placebo. Dose-related effects of the drug on the ability to keep a vehicle in lane (weaving) and to follow the speed changes of a lead car (car following) were compared within subjects for on-the-road versus in-simulator driving. Additionally, the outcomes of equivalence testing to alcohol-induced effects were investigated.\n\nRESULTS: Treatment effects found on weaving when driving in the simulator were comparable to treatment effects found when driving on the road. The effect after 10 mg Dronabinol was however less strong in the simulator than on the road and inter-individual variance seemed higher in the simulator. There was, however, a differential treatment effect of Dronabinol on reactions to speed changes of a lead car (car following) when driving on the road versus when driving in the simulator.\n\nCONCLUSION: The driving simulator was proven to be sensitive for demonstrating Dronabinol-induced effects particularly at higher doses. Treatment effects of Dronabinol on weaving were comparable with driving on the road but inter-individual variability seemed higher in the simulator than on the road which may have potential effects on the clinical inferences made from simulator driving. Car following on the road and in the simulator were, however, not comparable.
-
medicinal delta 9 tetrahydrocannabinol Dronabinol impairs on the road driving performance of occasional and heavy cannabis users but is not detected in standard field sobriety tests
Addiction, 2012Co-Authors: Wendy M Bosker, Gisela Skopp, Kim P C Kuypers, Eef L Theunissen, Anke Surinx, Roos J Blankespoor, W K Jeffery, H C Walls, C J Van Leeuwen, Johannes G. RamaekersAbstract:Aims The acute and chronic effects of Dronabinol [medicinal ?9-tetrahydrocannabinol (THC)] on actual driving performance and the Standard Field Sobriety Test (SFST) were assessed. It was hypothesized that occasional users would be impaired on these tests and that heavy users would show less impairment due to tolerance. Design, setting and participants Double-blind, placebo-controlled, randomized, three-way cross-over study. Twelve occasional and 12 heavy cannabis users (14 males/10 females) received single doses of placebo, 10 and 20?mg Dronabinol. Measurements Standard deviation of lateral position (SDLP; i.e. weaving) is the primary measure of road-tracking control. Time to speed adaptation (TSA) is the primary reaction-time measure in the car-following test. Percentage of impaired individuals on the SFST and subjective high on a visual analogue scale were secondary measures. Findings Superiority tests showed that SDLP (P?=?0.008) and TSA (P?=?0.011) increased after Dronabinol in occasional users. Equivalence tests demonstrated that Dronabinol-induced increments in SDLP were bigger than impairment associated with BAC of 0.5?mg/ml in occasional and heavy users, although the magnitude of driving impairment was generally less in heavy users. The SFST did not discriminate between conditions. Levels of subjective high were comparable in occasional and heavy users. Conclusions Dronabinol (medicinal tetrahydrocannabinol) impairs driving performance in occasional and heavy users in a dose-dependent way, but to a lesser degree in heavy users due possibly to tolerance. The Standard Field Sobriety Test is not sensitive to clinically relevant driving impairment caused by oral tetrahydrocannabinol.
-
medicinal δ 9 tetrahydrocannabinol Dronabinol impairs on the road driving performance of occasional and heavy cannabis users but is not detected in standard field sobriety tests
Addiction, 2012Co-Authors: Wendy M Bosker, Gisela Skopp, Kim P C Kuypers, Eef L Theunissen, Anke Surinx, Roos J Blankespoor, W K Jeffery, C J Van Leeuwen, Chip H Walls, Johannes G. RamaekersAbstract:AIMS: The acute and chronic effects of Dronabinol [medicinal Δ(9) -tetrahydrocannabinol (THC)] on actual driving performance and the Standard Field Sobriety Test (SFST) were assessed. It was hypothesized that occasional users would be impaired on these tests and that heavy users would show less impairment due to tolerance. DESIGN, SETTING AND PARTICIPANTS: Double-blind, placebo-controlled, randomized, three-way cross-over study. Twelve occasional and 12 heavy cannabis users (14 males/10 females) received single doses of placebo, 10 and 20 mg Dronabinol. MEASUREMENTS: Standard deviation of lateral position (SDLP; i.e. weaving) is the primary measure of road-tracking control. Time to speed adaptation (TSA) is the primary reaction-time measure in the car-following test. Percentage of impaired individuals on the SFST and subjective high on a visual analogue scale were secondary measures. FINDINGS: Superiority tests showed that SDLP (P = 0.008) and TSA (P = 0.011) increased after Dronabinol in occasional users. Equivalence tests demonstrated that Dronabinol-induced increments in SDLP were bigger than impairment associated with BAC of 0.5 mg/ml in occasional and heavy users, although the magnitude of driving impairment was generally less in heavy users. The SFST did not discriminate between conditions. Levels of subjective high were comparable in occasional and heavy users. CONCLUSIONS: Dronabinol (medicinal tetrahydrocannabinol) impairs driving performance in occasional and heavy users in a dose-dependent way, but to a lesser degree in heavy users due possibly to tolerance. The Standard Field Sobriety Test is not sensitive to clinically relevant driving impairment caused by oral tetrahydrocannabinol.
-
medicinal δ 9 tetrahydrocannabinol Dronabinol impairs on the road driving performance of occasional and heavy cannabis users but is not detected in standard field sobriety tests
Addiction, 2012Co-Authors: Wendy M Bosker, Gisela Skopp, Kim P C Kuypers, Eef L Theunissen, Anke Surinx, Roos J Blankespoor, W K Jeffery, Chip H Walls, Cees J Van Leeuwen, Johannes G. RamaekersAbstract:AIMS: The acute and chronic effects of Dronabinol (medicinal tetrahydrocannabinol) on actual driving performance and the Standard Field Sobriety Test (SFST) were assessed. It was hypothesized that occasional users would be impaired on these tests and that heavy users would show less impairment due to tolerance. DESIGN, SETTING AND PARTICIPANTS: Double-blind, placebo-controlled, randomized, 3-way cross-over study. Twelve occasional and twelve heavy cannabis users (14 males/ 10 females) received single doses of placebo, 10 and 20 mg Dronabinol. MEASUREMENTS: Standard deviation of lateral position (SDLP; i.e. weaving) is the primary measure of road tracking control. Time to speed adaptation (TSA) is the primary reaction time measure in the car-following test. Percentage of impaired individuals on the SFST and subjective high on a visual analogue scale were secondary measures. FINDINGS: Superiority tests showed that SDLP (p=0.008) and TSA (p=0.011) increased after Dronabinol in occasional users. Equivalence tests demonstrated that Dronabinol-induced increments in SDLP, were bigger than impairment associated with BAC of 0.5 mg/mL in occasional and heavy users, although the magnitude of driving impairment was generally less in heavy users. The SFST did not discriminate between conditions. Levels of subjective high were comparable in occasional and heavy users. CONCLUSIONS: Dronabinol (medicinal tetrahydrocannabinol) impairs driving performance in occasional and heavy users in a dose-dependent way, but to a lesser degree in heavy users possibly due to tolerance. The Standard Field Sobriety Test is not sensitive to clinically relevant driving impairment caused by oral tetrahydrocannabinol. Language: en
Richard W Foltin - One of the best experts on this subject based on the ideXlab platform.
-
CLINICAL SCIENCE Dronabinol and Marijuana in HIV-Positive Marijuana Smokers Caloric Intake, Mood, and Sleep
2015Co-Authors: Margaret Haney, Carl L Hart, Suzanne K Vosburg, Erik W Gunderson, Judith Rabkin, Ra D. Comer, Richard W FoltinAbstract:Objectives: Individuals with HIV constitute the largest group using cannabinoids for medicinal reasons; yet, no studies have directly compared the tolerability and efficacy of smoked marijuana and oral Dronabinol maintenance in HIV-positive marijuana smokers. This placebo-controlled within-subjects study evaluated marijuana and Dronabinol across a range of behaviors: eating topography, mood, cognitive performance, physiologic measures, and sleep. Methods: HIV-positive marijuana smokers (n = 10) completed 2 16-day inpatient phases. Each Dronabinol (5 and 10 mg) and marijuana (2.0 % and 3.9 % D9-tetrahydrocannabinol [THC]) dose was administered 4 times daily for 4 days, but only 1 drug was active per day, thereby maintaining double-blind dosing. Four days of placebo washout separated each active cannabinoid condition. Results: As compared with placebo, marijuana and Dronabinol dose dependently increased daily caloric intake and body weight in HIV-positive marijuana smokers. All cannabinoid conditions produced significant intoxication, except for low-dose Dronabinol (5 mg); the intoxication was rated positively (eg, ‘‘good drug effect’’) with little evidence of discomfort and no impairment of cognitive performance. Effects of marijuana and Dronabinol were comparable, except that only marijuana (3.9 % THC) improved ratings of sleep. Conclusions: These data suggest that for HIV-positive marijuana smokers, both Dronabinol (at doses 8 times current recommendations) and marijuana were well tolerated and produced substantial and comparable increases in food intake
-
nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse
Neuropsychopharmacology, 2013Co-Authors: Margaret Haney, Suzanne K Vosburg, Gillinder Bedi, Ziva D Cooper, Sandra D Comer, Richard W FoltinAbstract:Few individuals seeking treatment for marijuana use achieve sustained abstinence. The cannabinoid receptor agonist, Δ(9)-tetrahydrocannabinol (THC; Dronabinol), decreases marijuana withdrawal symptoms, yet does not decrease marijuana use in the laboratory or clinic. Dronabinol has poor bioavailability, which may contribute to its poor efficacy. The FDA-approved synthetic analog of THC, nabilone, has higher bioavailability and clearer dose-linearity than Dronabinol. This study tested whether nabilone administration would decrease marijuana withdrawal symptoms and a laboratory measure of marijuana relapse relative to placebo. Daily, nontreatment-seeking marijuana smokers (8 men and 3 women), who reported smoking 8.3±3.1 marijuana cigarettes/day completed this within-subject study comprising three, 8-day inpatient phases; each phase tested a different nabilone dose (0, 6, 8 mg/day, administered in counter-balanced order on days 2-8). On the first inpatient day, participants took placebo capsules and smoked active marijuana (5.6% THC) at six timepoints. For the next 3 days, they had the opportunity to self-administer placebo marijuana (0.0% THC; withdrawal), followed by 4 days in which active marijuana was available for self-administration (5.6% THC; relapse). Both nabilone dose conditions decreased marijuana relapse and reversed withdrawal-related irritability and disruptions in sleep and food intake (p<0.05). Nabilone (8 mg/day) modestly worsened psychomotor task performance. Neither dose condition increased ratings of capsule 'liking' or desire to take the capsules relative to placebo. Thus, nabilone maintenance produced a robust attenuation of marijuana withdrawal symptoms and a laboratory measure of relapse even with once per day dosing. These data support testing of nabilone for patients seeking marijuana treatment.
-
Dronabinol and marijuana in hiv marijuana smokers acute effects on caloric intake and mood
Psychopharmacology, 2005Co-Authors: Margaret Haney, Erik W Gunderson, Judith G Rabkin, Richard W FoltinAbstract:Rationale No studies to date have directly compared the tolerability and efficacy of smoked marijuana and oral Dronabinol in HIV+ marijuana smokers.
Erik W Gunderson - One of the best experts on this subject based on the ideXlab platform.
-
CLINICAL SCIENCE Dronabinol and Marijuana in HIV-Positive Marijuana Smokers Caloric Intake, Mood, and Sleep
2015Co-Authors: Margaret Haney, Carl L Hart, Suzanne K Vosburg, Erik W Gunderson, Judith Rabkin, Ra D. Comer, Richard W FoltinAbstract:Objectives: Individuals with HIV constitute the largest group using cannabinoids for medicinal reasons; yet, no studies have directly compared the tolerability and efficacy of smoked marijuana and oral Dronabinol maintenance in HIV-positive marijuana smokers. This placebo-controlled within-subjects study evaluated marijuana and Dronabinol across a range of behaviors: eating topography, mood, cognitive performance, physiologic measures, and sleep. Methods: HIV-positive marijuana smokers (n = 10) completed 2 16-day inpatient phases. Each Dronabinol (5 and 10 mg) and marijuana (2.0 % and 3.9 % D9-tetrahydrocannabinol [THC]) dose was administered 4 times daily for 4 days, but only 1 drug was active per day, thereby maintaining double-blind dosing. Four days of placebo washout separated each active cannabinoid condition. Results: As compared with placebo, marijuana and Dronabinol dose dependently increased daily caloric intake and body weight in HIV-positive marijuana smokers. All cannabinoid conditions produced significant intoxication, except for low-dose Dronabinol (5 mg); the intoxication was rated positively (eg, ‘‘good drug effect’’) with little evidence of discomfort and no impairment of cognitive performance. Effects of marijuana and Dronabinol were comparable, except that only marijuana (3.9 % THC) improved ratings of sleep. Conclusions: These data suggest that for HIV-positive marijuana smokers, both Dronabinol (at doses 8 times current recommendations) and marijuana were well tolerated and produced substantial and comparable increases in food intake
-
Dronabinol and marijuana in hiv positive marijuana smokers caloric intake mood and sleep
Journal of Acquired Immune Deficiency Syndromes, 2007Co-Authors: Erik W Gunderson, Carl L Hart, Judith G Rabkin, Suzanne K VosburgAbstract:Objectives: Individuals with HIV constitute the largest group using cannabinoids for medicinal reasons; yet, no studies have directly compared the tolerability and efficacy of smoked marijuana and oral Dronabinol maintenance in HIV-positive marijuana smokers. This placebo-controlled within-subjects study evaluated marijuana and Dronabinol across a range of behaviors: eating topography, mood, cognitive performance, physiologic measures, and sleep. Methods: HIV-positive marijuana smokers (n = 10) completed 2 16-day inpatient phases. Each Dronabinol (5 and 10 mg) and marijuana (2.0% and 3.9% D 9 -tetrahydrocannabinol [THC]) dosewas administered 4 times daily for 4 days, but only 1 drug was active per day, thereby maintaining double-blind dosing. Four days of placebo washout separated each active cannabinoid condition. Results: As compared with placebo, marijuana and Dronabinol dose dependently increased daily caloric intake and body weight in HIVpositive marijuana smokers. All cannabinoid conditions produced significant intoxication, except for low-dose Dronabinol (5 mg); the intoxication was rated positively (eg, ‘‘good drug effect’’) with little evidence of discomfort and no impairment of cognitive performance. Effects of marijuana and Dronabinol were comparable, except that only marijuana (3.9% THC) improved ratings of sleep. Conclusions: These data suggest that for HIV-positive marijuana smokers, both Dronabinol (at doses 8 times current recommendations) and marijuana were well tolerated and produced substantial and comparable increases in food intake.
-
Dronabinol and marijuana in hiv positive marijuana smokers caloric intake mood and sleep
Journal of Acquired Immune Deficiency Syndromes, 2007Co-Authors: Erik W Gunderson, Carl L Hart, Judith G Rabkin, Suzanne K VosburgAbstract:OBJECTIVES: Individuals with HIV constitute the largest group using cannabinoids for medicinal reasons; yet, no studies have directly compared the tolerability and efficacy of smoked marijuana and oral Dronabinol maintenance in HIV-positive marijuana smokers. This placebo-controlled within-subjects study evaluated marijuana and Dronabinol across a range of behaviors: eating topography, mood, cognitive performance, physiologic measures, and sleep. METHODS: HIV-positive marijuana smokers (n = 10) completed 2 16-day inpatient phases. Each Dronabinol (5 and 10 mg) and marijuana (2.0% and 3.9% Delta9-tetrahydrocannabinol [THC]) dose was administered 4 times daily for 4 days, but only 1 drug was active per day, thereby maintaining double-blind dosing. Four days of placebo washout separated each active cannabinoid condition. RESULTS: As compared with placebo, marijuana and Dronabinol dose dependently increased daily caloric intake and body weight in HIV-positive marijuana smokers. All cannabinoid conditions produced significant intoxication, except for low-dose Dronabinol (5 mg); the intoxication was rated positively (eg, "good drug effect") with little evidence of discomfort and no impairment of cognitive performance. Effects of marijuana and Dronabinol were comparable, except that only marijuana (3.9% THC) improved ratings of sleep. CONCLUSIONS: These data suggest that for HIV-positive marijuana smokers, both Dronabinol (at doses 8 times current recommendations) and marijuana were well tolerated and produced substantial and comparable increases in food intake.
-
Dronabinol and marijuana in hiv marijuana smokers acute effects on caloric intake and mood
Psychopharmacology, 2005Co-Authors: Margaret Haney, Erik W Gunderson, Judith G Rabkin, Richard W FoltinAbstract:Rationale No studies to date have directly compared the tolerability and efficacy of smoked marijuana and oral Dronabinol in HIV+ marijuana smokers.
Margaret Haney - One of the best experts on this subject based on the ideXlab platform.
-
CLINICAL SCIENCE Dronabinol and Marijuana in HIV-Positive Marijuana Smokers Caloric Intake, Mood, and Sleep
2015Co-Authors: Margaret Haney, Carl L Hart, Suzanne K Vosburg, Erik W Gunderson, Judith Rabkin, Ra D. Comer, Richard W FoltinAbstract:Objectives: Individuals with HIV constitute the largest group using cannabinoids for medicinal reasons; yet, no studies have directly compared the tolerability and efficacy of smoked marijuana and oral Dronabinol maintenance in HIV-positive marijuana smokers. This placebo-controlled within-subjects study evaluated marijuana and Dronabinol across a range of behaviors: eating topography, mood, cognitive performance, physiologic measures, and sleep. Methods: HIV-positive marijuana smokers (n = 10) completed 2 16-day inpatient phases. Each Dronabinol (5 and 10 mg) and marijuana (2.0 % and 3.9 % D9-tetrahydrocannabinol [THC]) dose was administered 4 times daily for 4 days, but only 1 drug was active per day, thereby maintaining double-blind dosing. Four days of placebo washout separated each active cannabinoid condition. Results: As compared with placebo, marijuana and Dronabinol dose dependently increased daily caloric intake and body weight in HIV-positive marijuana smokers. All cannabinoid conditions produced significant intoxication, except for low-dose Dronabinol (5 mg); the intoxication was rated positively (eg, ‘‘good drug effect’’) with little evidence of discomfort and no impairment of cognitive performance. Effects of marijuana and Dronabinol were comparable, except that only marijuana (3.9 % THC) improved ratings of sleep. Conclusions: These data suggest that for HIV-positive marijuana smokers, both Dronabinol (at doses 8 times current recommendations) and marijuana were well tolerated and produced substantial and comparable increases in food intake
-
subjective cognitive and cardiovascular dose effect profile of nabilone and Dronabinol in marijuana smokers
Addiction Biology, 2013Co-Authors: Gillinder Bedi, Ziva D Cooper, Margaret HaneyAbstract:: Marijuana dependence is a substantial public health problem, with existing treatments showing limited efficacy. In laboratory and clinical studies, the cannabinoid receptor 1 agonist oral Δ9tetrahydrocannabinol (THC; Dronabinol) has been shown to decrease marijuana withdrawal but not relapse. Dronabinol has poor bioavailability, potentially contributing to its failure to decrease relapse. The synthetic THC analogue, nabilone, has better bioavailability than Dronabinol. We therefore aimed to characterize nabilone's behavioral and physiological effects across a range of acute doses in current marijuana smokers and compare these with Dronabinol's effects. Participants (4 female; 10 male) smoking marijuana 6.6 (standard deviation = 0.7) days/week completed this outpatient, within-subjects, double-blind, randomized protocol. Over seven sessions, the time-dependent subjective, cognitive and cardiovascular effects of nabilone (2, 4, 6, 8 mg), Dronabinol (10, 20 mg) and placebo were assessed. Nabilone (4, 6, 8 mg) and Dronabinol (10, 20 mg) increased ratings of feeling a good effect, a strong effect and/or 'high' relative to placebo; nabilone had a slower onset of peak subjective effects than Dronabinol. Nabilone (6, 8 mg) modestly lowered psychomotor speed relative to placebo and Dronabinol. There were dose-dependent increases in heart rate after nabilone, and nabilone (2 mg) and Dronabinol (10 mg) decreased systolic blood pressure. Thus, nabilone produced sustained, dose-related increases in positive mood, few cognitive decrements and lawful cardiovascular alterations. It had a longer time to peak effects than Dronabinol, and effects were more dose-related, suggesting improved bioavailability. Nabilone was well tolerated by marijuana smokers, supporting further testing as a potential medication for marijuana dependence.
-
nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse
Neuropsychopharmacology, 2013Co-Authors: Margaret Haney, Suzanne K Vosburg, Gillinder Bedi, Ziva D Cooper, Sandra D Comer, Richard W FoltinAbstract:Few individuals seeking treatment for marijuana use achieve sustained abstinence. The cannabinoid receptor agonist, Δ(9)-tetrahydrocannabinol (THC; Dronabinol), decreases marijuana withdrawal symptoms, yet does not decrease marijuana use in the laboratory or clinic. Dronabinol has poor bioavailability, which may contribute to its poor efficacy. The FDA-approved synthetic analog of THC, nabilone, has higher bioavailability and clearer dose-linearity than Dronabinol. This study tested whether nabilone administration would decrease marijuana withdrawal symptoms and a laboratory measure of marijuana relapse relative to placebo. Daily, nontreatment-seeking marijuana smokers (8 men and 3 women), who reported smoking 8.3±3.1 marijuana cigarettes/day completed this within-subject study comprising three, 8-day inpatient phases; each phase tested a different nabilone dose (0, 6, 8 mg/day, administered in counter-balanced order on days 2-8). On the first inpatient day, participants took placebo capsules and smoked active marijuana (5.6% THC) at six timepoints. For the next 3 days, they had the opportunity to self-administer placebo marijuana (0.0% THC; withdrawal), followed by 4 days in which active marijuana was available for self-administration (5.6% THC; relapse). Both nabilone dose conditions decreased marijuana relapse and reversed withdrawal-related irritability and disruptions in sleep and food intake (p<0.05). Nabilone (8 mg/day) modestly worsened psychomotor task performance. Neither dose condition increased ratings of capsule 'liking' or desire to take the capsules relative to placebo. Thus, nabilone maintenance produced a robust attenuation of marijuana withdrawal symptoms and a laboratory measure of relapse even with once per day dosing. These data support testing of nabilone for patients seeking marijuana treatment.
-
Dronabinol and marijuana in hiv marijuana smokers acute effects on caloric intake and mood
Psychopharmacology, 2005Co-Authors: Margaret Haney, Erik W Gunderson, Judith G Rabkin, Richard W FoltinAbstract:Rationale No studies to date have directly compared the tolerability and efficacy of smoked marijuana and oral Dronabinol in HIV+ marijuana smokers.
